Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.

Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, Mueller I.

Antimicrob Agents Chemother. 2011 Sep;55(9):4479-81. doi: 10.1128/AAC.01552-10. Epub 2011 Jun 27.

2.

Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children.

Ross A, Maire N, Sicuri E, Smith T, Conteh L.

PLoS One. 2011 Apr 7;6(4):e18391. doi: 10.1371/journal.pone.0018391.

3.

A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc).

Wilson AL; IPTc Taskforce.

PLoS One. 2011 Feb 14;6(2):e16976. doi: 10.1371/journal.pone.0016976. Review.

4.

Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.

Salman S, Griffin S, Kose K, Pitus N, Winmai J, Moore B, Siba P, Ilett KF, Mueller I, Davis TM.

Antimicrob Agents Chemother. 2011 Apr;55(4):1693-700. doi: 10.1128/AAC.01075-10. Epub 2011 Jan 31.

5.

Community response to intermittent preventive treatment of malaria in infants (IPTi) in Papua New Guinea.

Pell C, Straus L, Phuanukoonnon S, Lupiwa S, Mueller I, Senn N, Siba P, Gysels M, Pool R.

Malar J. 2010 Dec 22;9:369. doi: 10.1186/1475-2875-9-369.

6.

Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission.

Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, Nale J, Kiniboro B, Buckee CO, Tavul L, Siba PM, Reeder JC, Barry AE.

Malar J. 2010 Nov 23;9:336. doi: 10.1186/1475-2875-9-336.

7.

Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay.

Wong RP, Karunajeewa H, Mueller I, Siba P, Zimmerman PA, Davis TM.

Antimicrob Agents Chemother. 2011 Feb;55(2):798-805. doi: 10.1128/AAC.00939-10. Epub 2010 Nov 15.

8.

Severe Plasmodium vivax malaria, Brazilian Amazon.

Alexandre MA, Ferreira CO, Siqueira AM, Magalhães BL, Mourão MP, Lacerda MV, Alecrim Md.

Emerg Infect Dis. 2010 Oct;16(10):1611-4. doi: 10.3201/eid1610.100685.

9.

Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance.

Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, Newman RD, Grobusch MP, Greenwood B, Chandramohan D, Gosling RD.

PLoS One. 2010 Sep 7;5(9):e12618. doi: 10.1371/journal.pone.0012618.

10.

The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa.

Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, Tediosi F, Biao P, Masika P, Matovu F, Otieno P, Gosling RD, Hamel M, Odhiambo FO, Grobusch MP, Kremsner PG, Chandramohan D, Aponte JJ, Egan A, Schellenberg D, Macete E, Slutsker L, Newman RD, Alonso P, Menéndez C, Tanner M.

PLoS One. 2010 Jun 15;5(6):e10313. doi: 10.1371/journal.pone.0010313.

11.

Intermittent preventive treatment against malaria: an update.

Gosling RD, Cairns ME, Chico RM, Chandramohan D.

Expert Rev Anti Infect Ther. 2010 May;8(5):589-606. doi: 10.1586/eri.10.36. Review.

PMID:
20455687
12.

Community effectiveness of intermittent preventive treatment for infants (IPTi) in rural southern Tanzania.

Armstrong Schellenberg JR, Shirima K, Maokola W, Manzi F, Mrisho M, Mushi A, Mshinda H, Alonso P, Tanner M, Schellenberg DM.

Am J Trop Med Hyg. 2010 May;82(5):772-81. doi: 10.4269/ajtmh.2010.09-0207.

13.

Indoor residual spraying for preventing malaria.

Pluess B, Tanser FC, Lengeler C, Sharp BL.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006657. doi: 10.1002/14651858.CD006657.pub2. Review.

PMID:
20393950
14.

Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial.

Odhiambo FO, Hamel MJ, Williamson J, Lindblade K, ter Kuile FO, Peterson E, Otieno P, Kariuki S, Vulule J, Slutsker L, Newman RD.

PLoS One. 2010 Apr 2;5(4):e10016. doi: 10.1371/journal.pone.0010016.

15.

The Chesson strain of Plasmodium vivax malaria; relationship between prepatent period, latent period and relapse rate.

CRAIGE B Jr, ALVING AS, et al.

J Infect Dis. 1947 May-Jun;80(3):228-36. No abstract available.

PMID:
20247930
16.

Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.

Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, Schöpflin S, Stanisic D, Betuela I, Blood-Zikursh M, Siba P, Felger I, Schofield L, Zimmerman P, Mueller I.

PLoS One. 2010 Feb 4;5(2):e9047. doi: 10.1371/journal.pone.0009047.

17.

Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.

Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka F.

Antimicrob Agents Chemother. 2010 Jan;54(1):52-9. doi: 10.1128/AAC.00679-09. Epub 2009 Oct 19.

18.

Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.

Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C.

Lancet. 2009 Oct 31;374(9700):1533-42. doi: 10.1016/S0140-6736(09)61258-7. Epub 2009 Sep 16. Review.

PMID:
19765816
19.

Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.

Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D.

Lancet. 2009 Oct 31;374(9700):1521-32. doi: 10.1016/S0140-6736(09)60997-1. Epub 2009 Sep 16.

PMID:
19765815
20.

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite.

Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA.

Lancet Infect Dis. 2009 Sep;9(9):555-66. doi: 10.1016/S1473-3099(09)70177-X. Review.

PMID:
19695492
Items per page

Supplemental Content

Write to the Help Desk